MoonLake Immunotherapeutics (MLTX) vs Mentari Therapeutics (MTRI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MoonLake Immunotherapeutics is the larger company by market cap ($942.1 million vs $856.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLTX | MTRI |
|---|---|---|
| Share price | $11.07 | $14.70 |
| Market cap | $942.13M | $856.94M |
| 1-day change | +0.36% | -3.57% |
| YTD return | -16.01% | — |
| 1-year return | -12.63% | — |
| 5-year return | +12.16% | — |
| EPS (TTM) | $-3.66 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-227.32M | — |
| 52-week high | $23.29 | $23.30 |
| 52-week low | $9.46 | $5.75 |
| Distance from 52-week high | -52.47% | -36.91% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +173.62% | — |
| Average volume | 1.64M | 19.42K |
| Shares outstanding | 85.11M | 58.30M |
| Employees | 130 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
About Mentari Therapeutics
MTRI stock →Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.
Health Care · Biotechnology: Pharmaceutical Preparations
MLTX vs MTRI FAQ
Which is bigger, MoonLake Immunotherapeutics or Mentari Therapeutics?
MoonLake Immunotherapeutics (MLTX) is larger, with a market capitalization of $942.13M compared with $856.94M for Mentari Therapeutics (MTRI).
Are MoonLake Immunotherapeutics and Mentari Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.